Targeting human prostate cancer with 111In‐labeled D2B IgG, F(ab′)2 and Fab fragments in nude mice with PSMA‐expressing xenografts

This study demonstrates the feasibility of D2B IgG, F(ab′)2 and Fab fragments for targeting PSMA‐expressing prostate cancer xenografts. Copyright © 2014 John Wiley & Sons, Ltd. The potential of the 111In‐labeled anti‐PSMA antibody D2B IgG, F(ab′)2 and Fab fragments for targeting prostate cancer was determined in mice with subcutaneous PSMA‐expressing prostate cancer xenografts. The PSMA‐expressing xenografts were clearly visualized with SPECT/CT. Highest accumulation in the tumor lesions was observed with 111In‐D2B IgG (94.8 ± 19.2% ID/g at 168 h p.i.). Renal accumulation of F(ab′)2 and Fab fragments might hamper the visualization of tumor lesions located in the vicinity of the kidneys. However, in settings where multiple images are required within a short time interval, 111In‐D2B F(ab′)2 and Fab fragments can be used.
Source: Contrast Media and Molecular Imaging - Category: Radiology Authors: Tags: Full Paper Source Type: research